FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO045 | FROM PROPHYLAXIS TO ENDOGENOUS CONTROL: A SIX-MONTH REAL-WORLD EXPERIENCE WITH VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY M. Basso1, A. Ferretti1, M. Sacco1, S. Lancellotti1, T. Pirozzi1, L. Di Gennaro1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
6PDF: 2 -
CO-80 | EMICIZUMAB PLASMA CONCENTRATIONS AND CLINICAL OUTCOMES IN ACQUIRED HEMOPHILIA A: A REAL-WORLD SINGLE-CENTER EXPERIENCE C. Simion1|2, E. Zanon1|2, C. Bulato1, B. Stocco1|2, F. Righetto1, F. Sartorello1, P. Simioni1|2 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; 2Hemophilia Center, Padova University Hospital, Italy
25PDF: 13 -
PO66 | Viscoelastic tests in disseminated intravascular coagulation associated with aortic aneurysm A. M. Pizzini1, C. Biasoli2, M. Bovara3, E. Gesuete1, A. Fusco1, C. Fantoni1, P. Pedrazzi2, R. Mancini3, M. Silingardi1 | 1Ambulatorio Emostasi & Trombosi, Dipartimento Medico, Ospedale Maggiore AUSL Bologna; 2SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche della Romagna; 3Laboratorio Unico Metropolitano AUSL Bologna, Italy
646PDF: 17 -
CO-27 | INNOVATIVE USE OF EPTACOG BETA TO TREAT ACUTE ELBOW HEMARTHROSIS IN A PEDIATRIC PATIENT WITH HEMOPHILIA B AND A HISTORY OF INHIBITORS, UNDERGOING SECONDARY PROPHYLAXIS WITH CONCIZUMAB L. Laterza1, P. Giordano2, G. Lassandro2 | 1University of Bari "Aldo Moro", Interdisciplinary Department of Medicine, Bari, Italy; 2Pediatric Haemophilia Center-AOUC Pol. Giovanni XXXIII, University of Bari “Aldo Moro”, Bari, Italy
29PDF: 15 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
674PDF: 27 -
CO-35 | TRANSITION FROM A PAEDIATRIC REFERRAL CENTER TO AN ADULT CENTER IN INHERITED BLEEDING DISORDERS: A REAL-WORLD COHORT STUDY I. Ricca1, A. Casson1, T. Martini2, B. Borsellino2, A. Barchieri1, G. Guido1, P. Ocello1, M. Tucciarone1, R. Albiani2, B. Pollio2, G. Delios1 | 1Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Italy; 2Centro Esperto Malattie Emorragiche Congenite in Età Pediatrica e della Donna in Gravidanza - SSD Medicina Trasfusionale Materno-Infantile e Traumatologica, Città della Salute e della Scienza di Torino, Italy
24PDF: 9 -
PO044 | UPDATING MANAGEMENT OF ACQUIRED HEMOPHILIA A USING EMICIZUMAB: REAL-WORLD OUTCOMES BY A COLLABORATIVE NETWORK OF 3 ITALIAN CENTERS MI. Tassoni1, BM. Roccon1, A. Dalla Salda2, R. Benedetti3, R. Rossi4, C. Cattabiani4, G. Quintavalle1, A. Casali2, D. Imberti3, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SOC Medicina Interna per acuti ad indirizzo metabolico ed emocoagulativo, Azienda USL IRCCS Reggio Emilia, Italy; 3Centro Emostasi e Trombosi, Medicina Interna, Azienda USL Piacenza, Italy; 4Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy
6PDF: 2 -
PO19 | Joint health status in patients with moderate hemophilia A: a cross-sectional multi-center study I.L. Calcaterra1, F. Picasso2, F. Valeri3, E. Baldacci4, M. Napolitano5, C. Guerrino1, E. Zanon6, C. Santoro4, S. Siragusa7, C. Martinoli2, M. Di Minno1 | 1Department of Clinical Medicine and Surgery, Regional Reference Centre for Coagulation Disorders, Federico II University, Naples; 2Department of Health Sciences “DISSAL”, Università di Genova; 3Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Turin; 4Haematology, Department of Translational and Precision Medicine, Sapienza University, Roma; 5Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo and Haematology Unit and Rare Disorders Hospital “V. Cervello”, Palermo; 6Haemophilia Centre, General Medicine, Padua University Hospital, Padua; 7Department PROMISE, University of Palermo, Italy
594PDF: 24 -
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis
2853PDF: 491Supplementary Files: 144 -
CO41 | Failure in assisted reproductive techniques: insights from the first registry E. Grandone1,3,4, C. Lodigiani2, D. Colaizzo3, M. Passaretti2, J. Khizroeva4, A. De Laurenzo3, P. Totaro5, E. Bucherini6, D. Baldini7, V. Bitsadze4, A. Makatsarya4, M. Mastroianno3, G. Piazza8, M. Othman9, M. Margaglione1 | 1University of Foggia, Italy; 2Humanitas University, Rozzano, Italy; 3IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy; 4First Sechenov University, Russia; 5Santa Maria Hospital, Bari, Italy; 6Angiologia, Faenza, Italy; 7Momo Fertilife, Bisceglie, Italy; 8Brigham Women Hospital, USA; 9Queen’s University, Kingston, Canada
572PDF: 14 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
558PDF: 24 -
CO48 | Gynecological involvement in females with congenital plasminogen deficiency type 1 C. Dalla Porta1,2, M.T. Sartori1, G. Saggiorato1, I. Cortella1, S.A. Malerba1,3, P. Simioni1 | 1First Medical Clinic, Department of Medicine - DIMED, Università degli Studi di Padova; 2Department of Medicine, Casa di Cura Villa Maria, Padova; 3Medicina Generale, Ospedale dell’Angelo, Mestre, Italy
565PDF: 19 -
PO127 | ANAPHYLACTIC REACTION TO RECOMBINANT ACTIVATED FVII IN A MILD HEMOPHILIA A PATIENT WITH INHIBITOR: A CASE REPORT I. Nichele, G. Carli, G. Marchesini, A. Tosetto | Haematology Department, S. Bortolo Hospital, Vicenza, Italy
2PDF: 2 -
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508CAT O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, P. Banerjee1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D.E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
513PDF: 115 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
616PDF: 135 -
PO39 | Bleeding events in Von Willebrand disease type 1 yearly treatable with desmopressin A. Gringeri1,2, P.M. Mannucci3, M. Gringeri4, G. Castaman5, F. Peyvandi3,6 | 1Fondazione Charta, Milan; 2Centro di Sanità Solidale, Lucca; 3Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan; 4Department of Medical Biotechnologies and Translational Medicine, Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan; 5Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze; 6Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
636PDF: 23 -
Diagnosis and management of abnormal uterine bleeding in adolescence An expert Consensus Statement of SIGO (Italian Society of Gynecology and Obstetrics) and SISET (Italian Society for the Study of Hemostasis and Thrombosis)
2848PDF: 730 -
PO003 | CATHETER-RELATED THROMBOSIS IN CANCER PATIENTS: A RETROSPECTIVE REAL-WORLD STUDY G. Autiero1|3, S.A. Malerba1|2|4, F. Busato1|2, D. Tolomio1|2, M. Dalla Vestra1|2, F. Presotto1|2 | 1U.O. Medicina Generale, Osp. Dell'Angelo, Venezia-Mestre, Italy; 2U.O. Angiologia, Osp. Dell'Angelo, Venezia-Mestre, Italy; 3Dip. Medicina Interna, Università degli Studi di Padova, Italy; 4U.O.C. Medicina Generale ad indirizzo trombotico ed emorragico, Università degli studi di Padova, Italy
5PDF: 2 -
PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm1, N.H. Eide1, K. Hveem2|3|4, N. Van Es5|6, V.M. Morelli1|7, S.K. Braekkan1|7, J.B. Hansen1|7 | 1Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; 2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 3HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Research, St. Olav University Hospital, Trondheim, Norway; 5Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 6Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; 7Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
464PDF: 94 -
CO-86 | A RARE CASE OF ACQUIRED HEMOPHILIA A ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
30PDF: 14 -
PO36 | EXTENDED DURATION REDUCED DOSE ANTICOAGULATION IN CANCER-ASSOCIATED THROMBOSIS: A REAL-WORLD COHORT WITH LONG TERM FOLLOW UP A. Bhide1, I. Welding1, O. Ogunbiyi1, S. Hawkins2, E. Greenlay1, N. Prasannan1, J. Westwood1, M. Thomas1 | 1Department of Clinical Haematology, University College London Hospital, London; 2Data Clinic, University College London, UK; A. Bhide and I. Welding joint First Authors
481PDF: 116 -
PO74 | Combined therapeutic approaches in a patient with hereditary hemorrhagic telangiectasia (HHT) and cardiovascular comorbidities M. Romeo, E. Cimino, P. Conca, I.L. Calcaterra, G. Iannuzzo, C. Caputo, M. Aversano, E. Franc, S. Donnarumma, C. De Luca, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
757PDF: 16 -
CO-64 | REAPPRAISAL OF DESMOPRESSIN FOR MANAGEMENT OF MILD/MODERATE VON WILLEBRAND DISEASE: RESULTS OF A RETROSPECTIVE ANALYSIS IN 127 ITALIAN PATIENTS SUGGEST FURTHER ORGANIZATION OF PROSPECTIVE OBSERVATIONAL STUDIES TO PREDICT DESMOPRESSIN FAILURE WITH IMMEDIATE VWF CONCENTRATES REQUIREMENT A.B. Federici1, G. Castaman2 | 1Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Polo Didattico Università di Milano, Italy; 2Centro Emofilia e Malattie Emorragiche Regione Toscana, Ospedale Careggi, Firenze, Italy
28PDF: 13 -
PO126 | HIGH-DOSE INTRAVENOUS IMMUNOGLOBULINS FOR LONG-TERM PREVENTION OF RECURRENT GASTROINTESTINAL BLEEDING IN A PATIENT WITH ACQUIRED VON WILLEBRAND SYNDROME ASSOCIATED WITH MGUS R. Benedetti1, G. Quintavalle2, V. Della Corte1, M.I. Tassoni1, B.M. Roccon1, D. Imberti1, A. Coppola2 | 1Centro Emostasi e Trombosi, Medicina Interna, Azienda USL di Piacenza, Italy; 2SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy
8PDF: 2 -
PO50 | SUB-ANALYSIS OF INTERIM RESULTS FROM A PHASE 2 STUDY INVESTIGATING REGN9933A2 AND REGN7508CAT FOR THE PREVENTION OF CONTACT-MEDIATED VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACTIVE CANCER UNDERGOING PERIPHERALLY INSERTED CENTRAL CATHETER PLACEMENT (ROXI-CATH) J. Zwicker1,2, A.P. Kithcart3, J. Kaplan3, Y-C. Cheng3, J.G. Raya3, J. Xiao3, S. Li3, K. Musgrave4, D.E. Gutstein3, G. Piazza5 | 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Weill Cornell Medical Center, New York, NY, USA; 3Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 4Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 5Brigham and Women’s Hospital, Boston, MA, USA
492PDF: 127 -
PO27 | URINE QUALITATIVE ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS IN ROUTINE CLINICAL PRACTICE F. Schieppati1|2, P. Gomez-Rosas1|3, C. Ambaglio1, V. Brusegan1, O.C. Cretu1, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4|5, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Heidelberg, Germany; 5DOASENSE GmbH, Heidelberg, Germany
440PDF: 96 -
PO07 | PLATELET INHIBITION BY THE NOVEL NITRIC OXIDE-DONOR NITROSOOXYPROPANOL M. Lindkvist, J. Jakobsson, F. Lynfeldt, B. Sandberg, K. Fransén, K. Nilsson, M. Grenegård | Cardiovascular Research Centre, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
435PDF: 106 -
CO-85 | ACQUIRED HEMOPHILIA A IN LIVER CIRRHOSIS: BALANCING HEMOSTASIS BETWEEN HIGH HEMORRHAGIC AND THROMBOTIC RISKS N. Portesi, G. Martini | ASST Spedali Civili di Brescia, Italy
26PDF: 17 -
CO-20 | REAL-WORLD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD INJURY IN A COHORT OF CHILDREN WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED WITH EMICIZUMAB B. Pollio1, B. Borsellino1|2, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
26PDF: 13 -
PO72 | Fondaparinux in patient with active tuberculosis T. Marrazzo1, R. Parrella2, A. Botta2, A. Pontarelli2, M.P. Ursi3, A. Karruli4, R. Albisinni5 | 1UOC Medicina Interna e dei Trapianti, Ospedale Monaldi, Napoli, Italy; 2UOC Malattie Infettive ad Indirizzo Respiratorio, Ospedale Cotugno Azienda dei Colli, Napoli, Italy; 3UOC MECAU Ospedale CTO Azienda dei Colli, Napoli, Italy; 4Malattie Infettive e Tropicali, Ospedale di Tirana, Albania; 5UOC CCH Generale, Ospedale Monaldi Azienda dei Colli, Napoli, Italy
629PDF: 16 -
PO092 | HEPARIN-INDUCED THROMBOCYTOPENIA IN A PATIENT WITH GUILLAIN-BARRÉ SYNDROME: A POSSIBLE LINK WITH IMMUNE DYSREGULATION S. Bernardi1, F. Cei2, R. Lavecchia3, L. Chiarugi4, R. Tarquini5 | 1Università degli Studi di Firenze, Italy; 2Osp. S. Giuseppe Empoli, Italy
8PDF: 2 -
PO013 | COMPLEX COAGULATION PROFILE IN ALG8-CDG: EXPANDING CLINICAL RECOGNITION OF A RARE DISORDER R. Santacroce1, M. Schiavulli2, G. D'Andrea1, G. Luca Tiscia3, F. Cappucci3, M.L. Tramontano2, E. Grandone3|4, M. Margaglione1 | 1Genetica Medica - Dip.to di Medicina Clinica e Sperimentale, Università di Foggia, Italy; 2Haemophilia and Congenital Bleeding Disorders, Treatment Center Santobono-Pausilipon Children Hospital, AORN, Napoli, Italy; 3Unità di Emostasi e Trombosi, IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo (FG), Italy; 4Ostericia e Ginecologia, Dip.to di Scienze Mediche e Chirurgiche, Università di Foggia, Italy
7PDF: 2 -
CO-61 | REAL-WORLD IMPLEMENTATION OF GENE THERAPY FOR HEMOPHILIA: A SHARED PATHWAY AMONG HEALTHCARE AUTHORITY, SPECIALIST CENTERS AND PATIENT ORGANIZATIONS IN THE EMILIA-ROMAGNA REGION A. Coppola1, L. Valdrè2, C. Biasoli3, E. Ferri Grazzi4, E. Rozzi5, M. Volta5, R. Giroldini6, A. Tagliaferri1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Malattie Emorragiche Congenite, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy; 3SSI Presa in Carico delle Malattie Emorragiche e Tromboemboliche, AUSL Romagna, Ospedale Bufalini, Cesena, Italy; 4FEDRED, Federazione delle Associazioni Emofilici della Regione Emilia Romagna, Italy; 5Servizio Assistenza Ospedaliera, Malattie Rare, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy; 6Area Governo del Farmaco e Dispositivi Medici, Direzione Generale Cura della Persona, Salute e Welfare, Regione Emilia Romagna, Italy
24PDF: 12 -
BEST-05 | LONG-TERM EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A: REAL-WORLD EXPERIENCE ACROSS ALL AGES A. Colombo1, I. Quaglia1, M.R. Fasulo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
72PDF: 12 -
PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY A. Makatsariya1, E. Beloborodova2,V. Bitsadze1, J. Khizroeva1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Oskolkova1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University Sechenov University, Moscow, Russia; 2MEDSI Network of Medical Centers, Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
464PDF: 94 -
CO-32 | TRAUMA MANAGEMENT IN SEVERE HEMOPHILIA A: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy
24PDF: 10 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
752PDF: 26 -
PO076 | ACQUIRED FACTOR V INHIBITOR WITH CONCOMITANT LUPUS ANTICOAGULANT: DIAGNOSTIC PITFALLS AND THERAPEUTIC CHALLENGES G. Gazzelli1, Y. Azzanelli1, C. Vernarecci1, F. Marotta1, F. Giacopelli1, E. Cenni2, V. Agostini2, L. Banov1, AC Molinari1 | 1IRCCS Istituto Giannina Gaslini, Italy; 2IRCSS AOM S. Martino Genova, Italy
8PDF: 2 -
CO-44 | EVALUATION OF THE DEVIATION BETWEEN PRESCRIBED AND RECOMMENDED EMICIZUMAB DOSING IN PATIENTS WITH CONGENITAL HEMOPHILIA A A.C. Giuffrida1, S. Abeysinghe Gunawardhana1, S. Amato2, F. Casoli2, C. Recchi2, M. Saggioro2, E. Bonetti3, M. Bodini1, G. Poli2 | 1Centro Emofilia, UOC Medicina Trasfusionale, AOUI Verona, Italy; 2UOC Laboratorio Analisi, AOUI Verona, Italy; 3UOC Oncoematologia Pediatrica, AOUI Verona, Italy
28PDF: 11 -
CO29 | Emergency room physicians and oral anticoagulants related bleeding D. Barcellona1,2, G. Melis1, A. Bussu1, M. Orrù1, Ml. Caddeo1, E. Antonucci2, A. Mameli1, F. Marongiu1,2 | 1SSD Emostasi e Trombosi, AOU Cagliari; 2Fondazione Arianna, Bologna, Italy
660PDF: 21 -
PO113 | A STRANGE CASE OF RECURRENT ISOLATED DIGITAL ARTERIAL THROMBOSIS M.M. Poggi, D. Bruni | SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy
6PDF: 3 -
PO012 | RECURRENT CENTRAL RETINAL VEIN THROMBOSIS IN A PATIENT WITH MILD HEMOPHILIA A AND HETEROZYGOSITY FOR THE PROTHROMBIN G20210A VARIANT I. Zatta1, E. Pacquola1, L. Di Daniel2, C. Simion3, E. Zanon3, P. Simioni3, S. Villalta2, L. Abbruzzese1 | 1Medicina Trasfusionale Osp. Ca’ Foncello, Treviso, Italy; 2Medicina Generale Osp. S. Giacomo, Castelfranco V.to, Italy; 3Clinica Medica 1° Azienda-Ospedale Università, Padova, Italy
6PDF: 2 -
CO039 | CLINICAL SAFETY AND MONITORING OF APIXABAN IN HEMODIALYSIS PATIENTS: A PROSPECTIVE STUDY S. Guglielmo1, M. Lovisotto1, E. De Bon2, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombosis and Haemostasis Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda Ulss 6 Euganea, Cittadella and Camposampiero, Padova, Italy
9PDF: 2 -
CO-60 | A TURNING POINT IN THE MANAGEMENT OF HEMOPHILIA B WITH INHIBITORS: OUTCOMES OF CONCIZUMAB PROPHYLAXIS IN TWO CHILDREN FROM EXPLORER10 G. Quintavalle1, A. Matichecchia1, M.I. Tassoni1, B.M. Roccon1, F. Riccardi1, R.P. Serra2, A. Tiri2, P. Bertolini2, A. Tagliaferri1, A. Coppola1 | 1Regional Hub Center for Hemophilia and Congenital Bleeding Disorders, University Hospital of Parma, Italy; 2Pediatric Hematology-Oncology Unit, University Hospital of Parma, Italy
25PDF: 15 -
PO47 | VENOUS THROMBOEMBOLISM IN BREAST CANCER: INSIGHTS FROM A SINGLE-CENTER COHORT S. Kozhukhov, N. Dovganych | SI “NSC “The M. D. Strazhesko Institute of Cardiology, Clinical and Regenerative Medicine of the National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine; 2Cardio-Oncology Center, Kyiv, Ukraine
480PDF: 110 -
CO047 | OXIDATIVE STRESS–RELATED PLATELET HO-1 AND MICRO-RNA MODULATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNDER ASPIRIN THERAPY R . Liani1, P.G. Simeone1, M. Alfonsetti1, M. Frezza1, B. Di Marco1, V. Sorrenti2, A. Russo2, C. Di Giacomo2, M. Gulisano2, M. Luongo3, F. Cipollone1, T. Colangelo4, L. Vanella2, F. Santilli1 | 1Dep. of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti, Italy; 2Dep. of Drug and Health Sciences, University of Catania, Italy; 3Immunotransfusion Service, Clinical Haematology of Chieti University Hospital, Italy; 4Dep. of Medical and Surgical Sciences, University of Foggia, Italy
11PDF: 1 -
CO-06 | ENHANCING SHARED DECISION-MAKING IN INHERITED BLEEDING DISORDERS: A SINGLE-CENTER QUALITY IMPROVEMENT INITIATIVE C. Manzi, L. Piscitelli, E. Zacchi, V. Caldi, L. Valdrè | Inherited Bleeding Disorders Unit, IRCCS AOU, Bologna, Italy
68PDF: 14 -
PO24 | WE ARE JUGGLING MANY POSSIBILITIES: HEALTHCARE PROFESSIONALS’ EXPERIENCES AND PERSPECTIVES ON INTERPRETATION OF PULMONARY EMBOLISM SIGNS AND SYMPTOMS IN PATIENTS WITH LUNG CANCER A.A. Højen1, M. Søgaard1, A.G. Ording1, M.R. Saugbjerg2, T.D. Christensen2|3, H.R. Jacobsen4, L. Jørgensen5, H. Enggaard5 | 1Danish Center for Health Services Research, Aalborg University Hospital; 2Department of Cardiothoracic Surgery, Aarhus University Hospital; 3Department of Clinical Medicine, Aarhus University Hospital; 4Department of Oncology, Aalborg University Hospital; 5Clinical Nursing Research Unit, Aalborg University Hospital, Denmark
483PDF: 97 -
PO112 | REFRAMING THE ENIGMA: ACQUIRED HEMOPHILIA A AS A HARBINGER OF HHV-8–ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE M. Palladino1, G. Gammaitoni1, C. Santoro2, M. Muscaritoli1 | 1Medicina Interna e Nutrizione Clinica-Dip. Medicina Traslazionale e di Precisione; 2Ematologia- Dip. Medicina Traslazionale e di Precisione, Umberto I Roma, Italy
6PDF: 2 -
PO149 | MANAGEMENT OF ANTITHROMBOTIC THERAPY IN A PATIENT WITH HEMOPHILIA C AND ATRIAL FIBRILLATION E. Marrone1, G. Ruggiero2, E. Cimino3, P. Conca3, C. Miele4, F. Gallucci1, A. Abate1, C. Romano1, D. Leosco2, U. Valentino1 | 1Department of Medicine 3, Cardarelli Hospital, Napoli, Italy; 2School of Specialization in Geriatrics; 3Department of Internal Medicine and Blood Coagulation; 4Department of Laboratory Medicine and Transfusion, Federico II University, Napoli, Italy
6PDF: 2 -
BEST-01 | IDENTIFICATION OF NOVEL HYPERACTIVE rFVIIa BYPASSING MOLECULES INFERRED BY ANCESTRAL SEQUENCE RECONSTRUCTION APPROACH M.F. Testa, I. Passerini, P. Santos, A. Benazzo, S. Ghirotto, F. Bernardi, A. Branchini, M. Pinotti, D. Balestra | Dep. of LSB, University of Ferrara, Italy
74PDF: 21 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
641PDF: 20 -
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience C. Simion, B. Stocco, E. Dalla Porta, E. Campello, G. Furlan, L. Spiezia, G. Saggiorato, F. Sartorello, E. Zanon, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
580PDF: 32 -
CO-30 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES M. Biglietto1|2, S. Sorella1, S. Ligia1, C. Andriola1, R. Mormile1, E. Baldacci1, A. Chistolini1, C. Santoro1 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Italy; 2Department of Molecular Biology, Sapienza University of Rome, Italy
32PDF: 16 -
PO81 | Direct oral anticoagulants in atypical site vein thrombosis: a single centre experience focused on cancer patients U. Mazzarelli1, A. Guida1, L. Agrelli1, M. Amato1, R. Guarrasi2, L. Santaniello2, C. Cardamone1, P. Vitale1, M. Triggiani1 | 1Centro per le Malattie Emorragiche Congenite e Malattie Trombotiche UOC Clinica Immunologica e Reumatologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno; 2UOC Clinica Oncologica AOU S. Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
631PDF: 23 -
PO160 | THE USE OF ANTIDEPRESSANT DRUGS AND BENZODIAZEPINE HYPNOTICS AS AN UNUSUAL RISK FACTOR FOR VTE G. Chiarelli, C. Caputo, M. Romeo, F. Strano, P. Conca, P. Rufolo, M.G. Mazzone, R. Russo, L. Valletta Jr., G. D’Errico, C. De Luca, E. Cimino, A. Tufano | DMCC. "Federico II" University of Naples, Italy
7PDF: 2 -
CO-01 | BLEEDING EVENTS IN MILD HEMOPHILIA A AND VON WILLEBRAND DISEASE TYPE 1 YEARLY TREATABLE WITH DESMOPRESSIN IN ITALY A. Gringeri1|2, P.M. Mannucci3, G.C. Castaman4, F. Peyvandi3|5 | 1Fondazione Charta, Milano, Italy; 2Centro di Sanità Solidale, Lucca, Italy; 3Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milano, Italy; 4Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy; 5Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
69PDF: 13 -
PO07 | Liver transplant in a case of congenital afibrinogenemia G. Murante1,2,3, S. Bergonzi1,2,3, C. Sella1,2,3, F. Valeri1,2, C. Dainese1,2, A. Valpreda4, R. Pastorino1,3, R. Romagnoli5, D. Patrono5, D. Cussa5, S. Martini6, B. Bruno2,3, A. Borchiellini1,2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin; 3Department of Molecular Biotechnology and Health Sciences, University of Turin; 4Central Laboratory Baldi and Riberi, AOU Città della Salute e della Scienza, Torino; 5General Surgery 2U - Liver Transplant Center, Molinette Hospital, AOU Città della Salute e della Scienza, Torino; 6SSD Hepatic insufficiency and Liver Transplant, AOU Città della Salute e della Scienza, Torino, Italy
577PDF: 15 -
PO130 | HEMORRHAGIC AND THROMBOTIC COMPLICATIONS DURING DOACS TREATMENT: THE IMPORTANCE OF A REGULAR AND PROLONGED FOLLOW-UP D. Barcellona1|2, A. Mameli2, S. Cornacchini2, P. Schirru2, L. Fenu2, V. Casu2, F. Marongiu1|2 | 1University of Cagliari, Italy; 2Haemostasis and Thrombosis Unit, Azienda Ospedaliero-Universitaria di Cagliari, Italy
6PDF: 2 -
PO071 | WHEN SJÖGREN’S DISEASE MIMICS TTP A. Castoldi, R. Rossio, F. Peyvandi | Medicina generale Osp. Maggiore Policlinico, Milano, Italy
6PDF: 3 -
CO011 | GENERATION OF A TARGETING NON-BLOCKING TISSUE FACTOR ANTIBODY FOR SAFE AND EFFICACIOUS CANCER TREATMENTS A. Metelli1, P. Nisticò1, J. Wrangle2 | 1IRCCS Regina Elena National Cancer Institute, Roma, Italy; 2Medical University of South Carolina, Charleston, USA
8PDF: 1 -
PO20 | Impact of endovascular treatment on functional outcome in ischemic stroke: a real-world retrospective study M.G. Mosconi1, G. Maraziti1, M. Paciaroni2, J. Fagotti3, V. Caso1 | 1Azienda Ospedaliera di Perugia; 2Università degli Studi di Ferrara; 3Ospedale San Giovanni Battista, Foligno (PG), Italy
655PDF: 17 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
434PDF: 92 -
PO94 | The use of antidepressant drugs and benzodiazepine hypnotics as an unusual risk factor for VTE G. Chiarelli, F. Strano, P. Conca, P. Rufolo, M. G. Mazzone, R. Russo, L. Jr Valletta, G. D’Errico, C. De Luca, E. Cimino, A. Tufano, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy
740PDF: 21 -
PO76 | Thrombosis associated with midline in autoimmune patient: a case report on the use of apixaban in a real-world setting M.V. Cherchi, M. Anedda, S. Che, M. Vacca, M. Caboni, M. Mantega | Department of Internal Medicine, ASL Sulcis, Italy
590PDF: 28 -
PO157 | DIAGNOSTIC CHALLENGES IN PREGNANCY-TRIGGERED IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA: A CASE FOR EARLY AND ACCURATE IDENTIFICATION M. Siepi1, G. Rescigno2 | 1UOC Patologia Clinica, AORN Santobono-Pausilipon, Napoli, Italy; 2UOC Patologia Clinica, AOU San Giovanni di Dio Ruggi d'Aragona, Salerno, Italy
6PDF: 2 -
PO099 | CORRELATION BETWEEN DIRECT ORAL ANTICOAGULANTS PLASMA LEVELS AND BRAIN VASCULAR EVENTS L. Riva1, M. Paolucci2, S. Forlivesi2, M. Gentile2, G. Casella1, A. Zini2, R. Marcucci3 | 1UOC Cardiologia Ospedale Maggiore AUSL Bologna, Italy; 2IRCCS Istituto delle Scienze Neurologiche di Bologna UOC Neurologia e Rete Stroke metropolitana Ospedale Maggiore AUSL Bologna, Italy; 3SOD Malattie Aterotrombotiche AOU Careggi Università degli Studi di Firenze, Italy
7PDF: 2 -
PO035 | ASSESSMENT OF HIGH-ON-TREATMENT PLATELET REACTIVITY IN PATIENTS ON DUAL ANTIPLATELET THERAPY USING THE FULLY AUTOMATED COAGULATION ANALYZER SYSMEX CN-6500: A COMPARATIVE STUDY WITH THREE POINT-OF-CARE TESTS E. Falcinelli1, L. Bury1, E. Giglio1, A.M. Mezzasoma1, V. Fazzi1, M. del Pinto2, M. Lenti3, A. Rechner2, P. Gresele1 | 1Dept of Medicine and Surgery, Section of Internal and Cardiovascular Medicine; 2Dept. of Cardiology; 3Dept of Vascular Surgery, University of Perugia, Italy; 4Sysmex Europe
6PDF: 2 -
PO128 | FROM SEVERE THROMBOSIS TO SUCCESSFUL PREGNANCIES: ORTHOTOPIC LIVER TRANSPLANTATION IN INHERITED AFIBRINOGENEMIA WITH BUDD–CHIARI SYNDROME G. Murante1|2|6, S. Bergonzi1|2|6, M. Capetta1|2|6, F. Valeri1|2, C. Dainese1|2, A. Valpreda4, R. Pastorino1|6, F. Bocchi1|6, R. Romagnoli5, S. Martini3, B. Bruno2|6, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases; 2Division of Hematology; 3SSD Hepatic insufficiency and Liver Transplant; 4Central Lab. Baldi and Riberi; 5General Surgery 2U - Liver Transplant Center, Molinette Hospital, AOU Città della Salute e della Scienza di Torino, Italy; 6Dep. of Molecular Biotechnology and Health Sciences, University of Turin, Italy
2PDF: 2 -
CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY M. Biglietto, B. Mandelli, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, S. Truglia, C. Santoro | Sapienza, University of Rome, Italy
11PDF: 3 -
PO87 | Intravascular leiomyomatosis extending to the right atrium: a case report with a multidisciplinary management M. Iorio1,2, C. Cavallaro1,2, E. Butera1,2, R. Talerico1,2, A. Gasbarrini2,3, R. Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Agostino Gemelli Polyclinic Foundation Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 2Università Cattolica del Sacro Cuore, Roma; 3Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
627PDF: 15 -
CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas1,2, M. Marchetti1,3, L. Russo1, C.J. Tartari1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca5, A. Falanga1,3 All on behalf of the Hypercan Investigators | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; 3School of Medicine and Surgery, University of Milan Bicocca, Italy; 4University Vita-Salute San Raffaele, Milan, Italy; 5Fondazione ARTET Onlus, Bergamo, Italy
631PDF: 16 -
CO-12 | BEYOND CLOTTING FACTORS: NURSING AS A CORNERSTONE OF LIFELONG HEMOPHILIA CARE M.V. Puliga1, C. Manzi2, A. Besagni3, S. Linari1, C. Carulli4, M. Morfini5 | 1SODc Malattie Emorragiche e della Coagulazione, AOU Careggi, Firenze, Italy; 2SSD Malattie Emorragiche Congenite, IRCCS Policlinico Sant'Orsola, Bologna, Italy; 3Indipendente, Italy; 4Clinica Ortopedica, Università di Firenze, SOD Ortopedia, AOU Careggi, Firenze, Italy; 5Associazione Italiana Centri Emofilia, AICE, Milano, Italy
73PDF: 14 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
463PDF: 98 -
PO085 | ACQUIRED HEMOPHILIA A IN THE SURGICAL PATIENT: DIAGNOSTIC AND THERAPEUTIC COMPLEXITY M. Luongo1, P. Massaro1, M. Di Mascio1, P.G. Simeone2, F. Santilli2, S. Verna1 | 1Immunohematology Service, Asl 02 Abruzzo, Chieti, Italy; 2Department of Medicine and Aging Sciences, and Center for Advanced Studies and Technology, “G. d’Annunzio” University of Chieti–Pescara, Italy
7PDF: 2 -
Development of a shared decision-making tool for gene therapy in hemophilia A in Italy
927PDF: 138SUPPLEMENTARY MATERIAL: 78 -
PO10 | RISK OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETERS: RESULTS FROM THE VIENNA CAT-BLED STUDY B. Sunder-Plassmann 1, N, Vladic1, C. Englisch1, F. Moik1|3, V. Sunder-Plassmann2, A. Berghoff2, M. Preusser2, I. Pabinger1, C. Ay1 | 1Division of Hematology and Haemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 2Division of Oncology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; 3Division of Oncology, Department of Internal Medicine, Medical University of Graz; Graz, Austria
476PDF: 120 -
CO-87 | SPONTANEOUS HEMATOMA IN A PATIENT WITH POLYCYTHEMIA VERA: A CASE OF ACQUIRED VON WILLEBRAND DISEASE? A. Strangio, A. Ierardi, M. Leotta, R.C. Santoro | Hemophilia center, AOU Renato Dulbecco, Catanzaro, Italy
32PDF: 14 -
PO032 | INHIBITION OF PLATELET ACTIVATION BY SMALL MOLECULE SYNTHETIC AGONISTS OF THE BILE ACID RECEPTOR: A NOVEL APPROACH TO ANTIPLATELET THERAPY L. Bury1, E. Falcinelli1, V. Fazzi1, C. Tili1, P. Gresele1, S. Fiorucci2 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine; 2Section of Gastroenterology, University of Perugia, Italy
2PDF: 2 -
CO-65 | COVID-19-ASSOCIATED HYPERCOAGULABILITY IN TYPE 2B VON WILLEBRAND DISEASE: INSIGHTS FROM GLOBAL HEMOSTATIC ASSAYS I. Condonato, C. Simion, E. Zanon, P. Simioni | Hemophilia Center, University Hospital of Padua, Italy
26PDF: 15 -
BEST-08 | PERIOPERATIVE MANAGEMENT OF CHILDREN WITH MILD FACTOR VII DEFICIENCY UNDERGOING SURGERY: A RETROSPECTIVE COHORT STUDY B. Borsellino1, T. Martini1, I. Ricca2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Transfusion Medicine, Ivrea Hospital, Ivrea, Italy
75PDF: 13 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
447PDF: 94 -
PO067 | LONG‑TERM SAFETY AND EFFECTIVENESS OF VITAMIN K ANTAGONISTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A RETROSPECTIVE COHORT ANALYSIS G. Sottilotta1, G. Praticò1, D. Megalizzi1, F. Luise2 | 1UOSD Centro per le Microcitemie - Servizio Emostasi e Trombosi; 2Laboratorio Analisi, Grande Ospedale Metropolitano di Reggio Calabria, Italy
7PDF: 2 -
CO-34 | SIMPLIFIED PERIOPERATIVE MANAGEMENT WITH N8-GP (TUROCTOCOG ALFA PEGOL) IN MAJOR ABDOMINAL SURGERY IN MILD HEMOPHILIA A WITH SEVERE BLEEDING PHENOTYPE: A CASE REPORT J. Di Paolo, R. Malizia, M. Luongo, P. Massaro, M. Di Mascio, S. Verna | Immunohematology Service, ASL 02 Abruzzo, Chieti, Italy
24PDF: 10 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
748PDF: 25
